LT2998296T - Cikloalkilo rūgšties darinys, jo gavimo būdas ir jo farmacinis taikymas - Google Patents

Cikloalkilo rūgšties darinys, jo gavimo būdas ir jo farmacinis taikymas

Info

Publication number
LT2998296T
LT2998296T LTEP14798044.5T LT14798044T LT2998296T LT 2998296 T LT2998296 T LT 2998296T LT 14798044 T LT14798044 T LT 14798044T LT 2998296 T LT2998296 T LT 2998296T
Authority
LT
Lithuania
Prior art keywords
preparation
acid derivative
pharmaceutical application
cycloalkyl acid
cycloalkyl
Prior art date
Application number
LTEP14798044.5T
Other languages
English (en)
Inventor
Jianbiao PENG
Piaoyang Sun
Jiong Lan
Chunyan GU
Xiaotao Li
Bonian Liu
Chunzhou HAN
Qiyue Hu
Fangfang JIN
Qing Dong
Guoqing Cao
Original Assignee
Shanghai Hengrui Pharmaceutical Co. Ltd.
Jiangsu Hengrui Medicine Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd. filed Critical Shanghai Hengrui Pharmaceutical Co. Ltd.
Publication of LT2998296T publication Critical patent/LT2998296T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP14798044.5T 2013-05-13 2014-04-29 Cikloalkilo rūgšties darinys, jo gavimo būdas ir jo farmacinis taikymas LT2998296T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310174990 2013-05-13
PCT/CN2014/076447 WO2014183555A1 (zh) 2013-05-13 2014-04-29 环烷基甲酸类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
LT2998296T true LT2998296T (lt) 2018-08-10

Family

ID=51897690

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14798044.5T LT2998296T (lt) 2013-05-13 2014-04-29 Cikloalkilo rūgšties darinys, jo gavimo būdas ir jo farmacinis taikymas

Country Status (21)

Country Link
US (1) US9637484B2 (lt)
EP (1) EP2998296B1 (lt)
JP (1) JP6440690B2 (lt)
KR (1) KR102240158B1 (lt)
CN (1) CN104470898B (lt)
AU (1) AU2014267974B2 (lt)
BR (1) BR112015027303B1 (lt)
CA (1) CA2923269C (lt)
CY (1) CY1120515T1 (lt)
DK (1) DK2998296T3 (lt)
ES (1) ES2668721T3 (lt)
HK (1) HK1205118A1 (lt)
HU (1) HUE037512T2 (lt)
LT (1) LT2998296T (lt)
MX (1) MX362747B (lt)
NO (1) NO2998296T3 (lt)
PL (1) PL2998296T3 (lt)
PT (1) PT2998296T (lt)
TR (1) TR201807104T4 (lt)
TW (1) TWI654172B (lt)
WO (1) WO2014183555A1 (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014319A (es) * 2015-05-27 2018-03-07 Jiangsu Hengrui Medicine Co Sal sodica de inhibidor de transportador de acido urico y su forma cristalina.
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
CN106831569B (zh) * 2015-12-07 2020-07-17 成都海创药业有限公司 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108201529B (zh) * 2016-12-16 2021-10-08 江苏恒瑞医药股份有限公司 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法
CN111386268B (zh) * 2017-11-23 2022-04-19 东宝紫星(杭州)生物医药有限公司 一种urat1抑制剂的晶型及其制备方法
CN110452168B (zh) * 2018-05-07 2022-03-15 中国医学科学院药物研究所 N-苯基-n-喹啉羧酸类化合物及其制法和药物用途
CN110467571B (zh) * 2018-05-11 2021-02-26 江苏恒瑞医药股份有限公司 一种制备环烷基甲酸类衍生物或其可药用盐的方法
JP2022505976A (ja) * 2018-11-02 2022-01-14 ジエンス ヘンルイ メデイシンカンパニー リミテッド 痛風または高尿酸血症の治療のための薬剤の調製における化合物ａおよび化合物ｂの併用
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN114315705B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与用途
CN115385854B (zh) * 2021-05-19 2024-04-09 江苏正大清江制药有限公司 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
AR053602A1 (es) 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
WO2008124083A2 (en) 2007-04-05 2008-10-16 Amgen Inc. Aurora kinase modulators and method of use
WO2008153129A1 (ja) 2007-06-14 2008-12-18 Teijin Pharma Limited 尿酸値低下剤
EA201270666A1 (ru) 2007-11-27 2012-12-28 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2010044403A1 (ja) 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 ５員環ヘテロアリール誘導体及びその医薬用途
CN102573462B (zh) 2009-10-13 2014-04-16 维尔斯达医疗公司 用于降低尿酸的3位取代的化合物
JP5709146B2 (ja) * 2010-06-16 2015-04-30 アルデア バイオサイエンシーズ インク． フェニルチオ酢酸化合物、組成物、および、その使用方法
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato

Also Published As

Publication number Publication date
EP2998296A4 (en) 2016-12-14
MX2015015393A (es) 2016-03-15
AU2014267974A1 (en) 2015-11-12
CA2923269C (en) 2023-02-14
WO2014183555A1 (zh) 2014-11-20
KR102240158B1 (ko) 2021-04-15
EP2998296A1 (en) 2016-03-23
DK2998296T3 (en) 2018-05-22
HK1205118A1 (zh) 2015-12-11
CN104470898B (zh) 2016-04-06
ES2668721T3 (es) 2018-05-21
BR112015027303A2 (lt) 2017-09-05
TWI654172B (zh) 2019-03-21
HUE037512T2 (hu) 2018-08-28
BR112015027303B1 (pt) 2023-04-25
PL2998296T3 (pl) 2018-12-31
TW201443010A (zh) 2014-11-16
NO2998296T3 (lt) 2018-08-11
CN104470898A (zh) 2015-03-25
KR20160006207A (ko) 2016-01-18
US20160108035A1 (en) 2016-04-21
PT2998296T (pt) 2018-06-15
JP2016520072A (ja) 2016-07-11
AU2014267974B2 (en) 2018-08-30
JP6440690B2 (ja) 2018-12-19
CY1120515T1 (el) 2019-07-10
CA2923269A1 (en) 2014-11-20
TR201807104T4 (tr) 2018-06-21
EP2998296B1 (en) 2018-03-14
MX362747B (es) 2019-02-05
US9637484B2 (en) 2017-05-02

Similar Documents

Publication Publication Date Title
HK1205118A1 (zh) 環烷基甲酸類衍生物、其製備方法及其在醫藥上的應用
HK1207063A1 (en) Aromatic amide derivative as well as preparation method and medicinal application thereof
HK1212980A1 (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
EP2884394A4 (en) ADMINISTRATION SYSTEM AND DELIVERY METHOD
HK1215567A1 (zh) 五元併六元雜環化合物、其製備方法、藥物組合物和應用
EP3040331A4 (en) Tetrahydrocyclopentapyrrole derivative and preparation method therefor
EP2962752A4 (en) VESICLE CONTAINING A SUBSTANCE, AND PROCESS FOR PRODUCING THE SAME
ZA201601343B (en) Vancomycin derivative, and preparation method and application thereof
SI3064498T1 (sl) Derivati pirazolopirimidona ali pirolotriazona, postopki priprave le-teh in farmacevtske uporabe le-teh
EP3012256A4 (en) HETEROCYCLIC BENZIMIDAZOLE-2-PIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARATION AND USE THEREOF
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
EP3072895A4 (en) Phillygenol sulphate and derivative thereof, and preparation method and application thereof
HK1206329A1 (en) Phenol derivative, method of preparing same, and pharmaceutical application of same
GB201318686D0 (en) Pharmaceutical preparations
EP2952519A4 (en) PROTOPANOXADIOL DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
EP2805956A4 (en) GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
GB201301721D0 (en) Pharmaceutical Preparations
IL242704B (en) Pharmacy preparation
EP3078659A4 (en) 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3040067A4 (en) Chlorogenic acid powder-injection and preparation method thereof
HK1244814A1 (zh) 一種薯蕷皂苷元-3-位衍生物及其製備方法和用途
IL240447A0 (en) Propionic-biaryl acid derivatives and their use as pharmaceutical preparations
EP3000807A4 (en) Mercaptonicotinic acid compound and preparation method and use thereof
IL240422B (en) Bi-aryl derivatives of propionic acid and their use as medicinal preparations
ZA201408723B (en) Emulsion for pharmaceutical use and method for the production thereof